STEP-HFpEF DM (Completed)
To evaluate the effect of semaglutide (GLP-1) in patients with obesity, Type II diabetes and chronic HFpEF on heart failure disease-specific symptoms, health status and quality of life, when compared with placebo
- Medicine
- semaglutide
- Population
- Heart failure
- Phase
- III
- Starting year
- 2021